Validity and reliability of the Serbian version of Patient-Reported Impact of Spasticity Measure in multiple sclerosis

International Journal of Rehabilitation Research

Volumn 38, Issue 3, 2015, Pages 199-205

  Knezevic, Tatjana ^a   Konstantinovic, Ljubica ^b,c   Rodic, Sindi ^b,c   Foti, Calogero ^d   Drulovic, Jelena ^b,c   Dackovic, Jelena ^c   Nikolic, Dejan ^a,b   Petronic, Ivana ^a,b   Stokic, Dobrivoje S ^e  

^a UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e METHODIST REHABILITATION CENTER   (United States)

Author keywords

multiple sclerosis; Patient Reported Impact of Spasticity Measure scale; reliability; spasticity; validity

Indexed keywords

NEUROMUSCULAR REHABILITATION; PATIENT MONITORING; RELIABILITY; TRANSLATION (LANGUAGES);

INTRACLASS CORRELATION COEFFICIENTS; MODIFIED ASHWORTH SCALE; MULTIPLE SCLEROSIS; PSYCHOMETRIC PROPERTIES; SPASTICITY; SPINAL CORD INJURIES (SCI); TEST-RETEST RELIABILITY; VALIDITY;

PRISMS;

CROSS-SECTIONAL STUDY; DISABILITY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PSYCHOLOGY; PSYCHOMETRY; PUBLICATION; QUALITY OF LIFE; REPRODUCIBILITY; SERBIA; SPASTICITY; VALIDATION STUDY;

CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SERBIA; TRANSLATIONS;

EID: 84939565347     PISSN: 03425282     EISSN: 14735660     Source Type: Journal    
DOI: 10.1097/MRR.0000000000000107     Document Type: Article

References (26)

1. Ashworth B. (1964). Preliminary trial of carisoprodol in mutiple sclerosis. Practitioner 192: 540-542
2. Barnes MP, Kent RM, Semlyen JK, McMullen KM. (2003). Spasticity in multiple sclerosis. Neurorehabil Neural Repair 17: 66-70
3. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. (2000). Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 25: 3186-3191
4. Berger T. (2013). Multiple sclerosis spasticity daily management: retrospective data from Europe. Expert Rev Neurother 13 (Suppl 1): 3-7
5. Berger T, Reindl M. (2007). Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J Neurol Sci 259: 21-26
6. Bohannon RW, Smith MB. (1987). Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67: 206-207
7. Bullinger M, Alonso J, Apolone G, Leplège A, Sullivan M, Wood-Dauphinee S, et al. (1998). Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol 51: 913-923
8. Cohen J. (1988). Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum
9. Cook KF, Teal CR, Engebretson JC, Hart KA, Mahoney JS, Robinson-Whelen S, Sherwood AM. (2007). Development and validation of Patient Reported Impact of Spasticity Measure (PRISM). J Rehabil Res Dev 44: 363-371
10. Cortina JM. (1993). What is coefficient alpha?. An examination of theory and applications. J Appl Psychol 78: 98-104
11. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. (2008). Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebocontrolled trial. Clin Ther 30: 974-985
12. Flachenecker P, Henze T, Zettl UK. (2014). Spasticity in patients with multiple sclerosis -clinical characteristics, treatment and quality of life. Acta Neurol Scand 129: 154-162
13. Fleiss JL. (1981). Statistical methods for rates and proportions, 2nd ed. New York: John Wiley Sons
14. George D, Mallery P. (2002). SPSS forWindows step by step: a simple guide and reference 110 update. Boston, Massachusetts: Allyn & Bacon
15. Gracies JM, Bayle N, Vinti M, Alkandari S, Vu P, Loche CM, Colas C. (2010). Fivestep clinical assessment in spastic paresis. Eur J Phys Rehabil Med 46: 411-421
16. Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, et al. (2006). Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129 (Pt 1): 224-234
17. Kurtzke JF. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452
18. Li F, Wu Y, Li X. (2014). Test-retest reliability and inter-rater reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in hemiplegic patients with stroke. Eur J Phys Rehabil Med 50: 9-15
19. McHorney CA, Tarlov AR. (1995). Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual Life Res 4: 293-307
20. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, et al. (2010). The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 10: 22
21. Morley A, Tod A, Cramp M, Mawson S. (2013). The meaning of spasticity to people with multiple sclerosis: what can health professionals learn?. Disabil Rehabil 35: 1284-1292
22. Oreja-Guevara C, González-Segura D, Vila C. (2013). Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci 123: 400-8
23. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. (1999). A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 13: 373-383
24. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. (2004). Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 10: 589-595
25. Walter SD, Eliasziw M, Donner A. (1998). Sample size and optimal designs for reliability studies. Stat Med 17: 101-110
26. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. (2005). Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 8: 94-104